Commentary on the MID3 Good Practices Paper.

Last updated on 22-8-2019 by Anonymous (niet gecontroleerd)

Peer reviewed scientific article




During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA — European Federation of Pharmaceutical Industries and Associations (EFPIA) Workshop on Modelling and Simulation, European regulators agreed to the necessity to build expertise to be able to review M&S data provided by companies in their dossier. This led to the establishment of the EMA Modelling and Simulation Working Group (MSWG

Associated health topics:

QR code

QR code for this page URL